Auxilium Pharmaceuticals Inc

Auxilium Pharmaceuticals — Merger or Acquisition (October 2014)

10 slides from Auxilium Pharmaceuticals's merger presentation, Oct 10, 2014

  1. Slide 1: Rule 425 filing legend

    Filed by Endo International plc (Commission File No. 001-36326) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Auxilium Pharmaceuticals, Inc. (Commission File No. 001-36628) The following slide

  2. Slide 2: Endo Town Hall Fall 2014

    Endo Town Hall Fall 2014 Rajiv De Silva President and Chief Executive Officer ©2014 Endo Pharmaceuticals Inc. All rights reserved.

  3. Slide 3: Additional Information

    Additional Information ADDITIONAL INFORMATION This communication does not constitute an offer to buy or solicitation of an offer to sell any securities. This communication relates to a proposed business combination transaction between Endo International plc ("Endo") and Auxilium Pharmaceuticals, Inc

  4. Slide 4: Forward-Looking Statements

    Forward-Looking Statements This communication may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Canadian securities legislation. These forward-looking statements include, but are not limited to, statements regardingthe proposed tran

  5. Slide 5: Our Journey to Date

    Our Journey to Date Restructured for efficiency and strengthened the organization Increased focus on core businesses to maximize organic growth potential Divested HealthTronics due to limited fit with company strategy Transformational transaction with Paladin Labs resulting in re-domicile to Ireland

  6. Slide 6: The Next Step: A Compelling Combination

    The Next Step: A Compelling Combination Aligns with Endo’s strategy of pursuing accretive, value creating growth opportunities Enhances Endo's branded pharmaceutical business with the addition of Auxilium's leading men's healthcare products and development portfolio Accelerates growth of and maximiz

  7. Slide 7: Auxilium Snapshot

    Auxilium Snapshot Ticker: NASDAQ “AUXL” Headquarters: Chesterbrook, Pennsylvania Founded: 1999 Headcount: ~480 employees Specialty biopharmaceutical company with a focus on developing and commercializing innovative products for specialist audiences Emerging leader in men's healthcare and has strateg

  8. Slide 8: Combination Aligns with Endo's Strategic Direction

    Combination Aligns with Endo’s Strategic Direction Endo executing strategic plan to enhance shareholder value Meeting or exceeding financial targets Maximizing the growth potential of core businesses Continued investment in de-risked R&D Lean and efficient operating model Pursuing accretive value cr

  9. Slide 9: Accelerating Organic Growth

    Accelerating Organic Growth Auxilium’s FDA-approved products in urology, orthopedics, and other areas are natural complements to men’s health and pain products in Endo’s branded pharmaceuticals portfolio Endo expects to optimize Auxilium’s portfolio of products by leveraging scale, competencies and

  10. Slide 10: Select Highlights of Complementary Product Portfolio

    Select Highlights of Complementary Product Portfolio Men’s Health / Urology Orthopedics / Pain Other Specialty 9 ©2014 Endo Pharmaceuticals Inc. All rights reserved.

Auxilium Pharmaceuticals — Merger or Acquisition (October 2014) on 6ix